FDA Approved: SYNJARDY XR — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved a supplemental application for SYNJARDY XR, a fixed-dose combination of empagliflozin and metformin hydrochloride.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• SYNJARDY XR (Empagliflozin, Metformin hydrochloride)

Snippet

SUPPL AP for SYNJARDY XR (EMPAGLIFLOZIN, METFORMIN HYDROCHLORIDE)